Focus on levomepromazine

Current Medical Research and Opinion

Volumn 20, Issue 12, 2004, Pages 1877-1881

  Green, Ben ^a,b   Pettit, Tor ^a   Faith, Lesley ^a   Seaton, Kristof ^c  

^a Cheadle Royal Hospital   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c STEPPING HILL HOSPITAL   (United Kingdom)

Author keywords

Antipsychotic; Anxiolytic; Methotrimeprazine; Phenothiazines; Schizoaffective disorder; Schizophrenia

Indexed keywords

ALCOHOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CHLORPROTHIXENE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A2; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; HALOPERIDOL; LEVOMEPROMAZINE; LEVOMEPROMAZINE SULFOXIDE; NEUROLEPTIC AGENT; NORCITALOPRAM; NORLEVOMEPROMAZINE; PROTHIPENDYL; RISPERIDONE; SEROTONIN 2 ANTAGONIST; UNCLASSIFIED DRUG;

AGITATION; AGRANULOCYTOSIS; AMENORRHEA; BEHAVIOR DISORDER; BLISTER; BONE MARROW DEPRESSION; BRONCHOSPASM; CLINICAL TRIAL; COLLAPSE; COMA; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; DERMATITIS; DISORIENTATION; DROWSINESS; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG OVERDOSE; EMBASE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEVER; FIRST PASS EFFECT; GALACTORRHEA; GRAND MAL EPILEPSY; GYNECOMASTIA; HALLUCINATION; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTHYROIDISM; HYPOTENSION; HYPOTHERMIA; HYPOVENTILATION; IMPOTENCE; INJECTION SITE REACTION; INTENSIVE CARE; LETHARGY; MEDLINE; MICTURITION DISORDER; MUSCLE HYPOTONIA; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; OBSTRUCTIVE JAUNDICE; ORTHOSTATIC HYPOTENSION; PAIN; PANCYTOPENIA; PHOTOTOXICITY; POSTOPERATIVE ANALGESIA; PSYCINFO; RASH; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SHORT SURVEY; SIDE EFFECT; SPEECH DISORDER; SUICIDAL BEHAVIOR; TACHYCARDIA; TERMINAL CARE; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BRONCHOCONSTRICTION; DRUG RESISTANCE; HUMANS; METHOTRIMEPRAZINE; NAUSEA; PAIN; SCHIZOPHRENIA; SUICIDE; TREATMENT OUTCOME;

EID: 13144257701     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X12708     Document Type: Short Survey

References (26)

1. Madsen F, Faurschou P, Banning AM, Engel AM, Sjogren P, Rosetzsky A. The protective effect of inhaled levomepromazine (Nozinan) on histamine-induced bronchial constriction. Pulm Pharmacol 1993;6(2):129-36 [erratum appears in Pulm Pharmacol 1993;(4):287]
2. Madsen F, Faurschou P, Banning AM, Engel AM, Sjogren P, Rosetzsky A. The protective effect of inhaled levomepromazine (Nozinan) on histamine-induced bronchial constriction. Pulm Pharmacol 1993;6(2):129-36 [erratum appears in Pulm Pharmacol 1993;(4):287]
3. Costantini D, Trifogli R, Fiaschetti T. On the use of Nozinan (levomepromazine) in preanesthetic medication [Italian]. Acta Anaesthesiologica 1968:Suppl 8:277 and Dahl SG, Hall H. Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat. Psychopharmacology 1981;74(2):101-4
4. Costantini D, Trifogli R, Fiaschetti T. On the use of Nozinan (levomepromazine) in preanesthetic medication [Italian]. Acta Anaesthesiologica 1968:Suppl 8:277 and Dahl SG, Hall H. Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat. Psychopharmacology 1981;74(2):101-4
5. McGee JL, Alexander MR. Phenothiazine analgesia - fact or fantasy? [review; 56 refs]. Am J Hosp Pharm 1979;36(5):633-40
6. Fazio AN. Control of postoperative pain: a comparison of the efficacy and safety of pentazocine, methotrimeprazine, meperidine, and a placebo. Curr Ther Res Clin Exp 1070;12(2):73-7
7. Skinner J, Skinner A. Levomepromazine for nausea and vomiting in advanced cancer [review; 10 refs]. Hosp Med (Lond) 1999;60(8):568-70
8. Molnar J, Beladi I, Foldes I. Studies on antituberculotic action of some phenothiazine derivatives in vitro. Zentralblatt fur Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene - Erste Abteilung Originale - Reihe A: Medizinische Mikrobiologie und Parasitologie 1977;239(4):521-6
9. Avis SP, Holzbecher MD. A fatal case of methotrimeprazine overdose. J Forensic Sci 1996;41(6):1080-1
10. Dahl SG. Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 1976;19(4):435-42
11. Dahl SG, Strandjord RE, Sigfusson S. Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol 1977;11(4):305-10
12. Lal S, Nair NP, Cecyre D, Quirion R. Levomepromazine receptor binding profile in human brain-implications for treatment-resistant schizophrenia. Acta Psychiatr Scand 1993;87(6):380-3
13. Antkiewicz-Michaluk L. The influence of chronic treatment with antidepressant neuroleptics on the central serotonin system. Pol J Pharmacol Pharm 1986;38(4):359-70
14. Dahl SG, Hall H. Binding affinity of levomepromazine and two of its major metabolites of central dopamine and alpha-adrenergic receptors in the rat. Psychopharmacology 1981;74(2):101-4
15. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol 1996;16(1):38-44
16. Lal S, Nair NP. Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatr Scand 1992;85(3):243-5
17. Nygaard HA, Fuglum E, Elgen K. Zuclopenthixol, melperone and haloperidol/levomepromazine in the elderly. Meta-analysis of two double-blind trials at 15 nursing homes in Norway. Curr Med Res Opin 1992;12(10):615-22
18. Maryniak O, Manchanda R, Velani A. Methotrimeprazine in the treatment of agitation in acquired brain injury patients. Brain Injury 2001;15(2):167-74
19. Garzotto N, Burti L, Tansella M. A fatal case of pancytopenia due to levomepromazine. Br J Psychiatry 1976;129:443-5
20. Ananth JV, Lehmann HE, Ban TA. Agranulocytosis associated with methotrimeprazine (Nozinan) administration: a report of three cases. Can Med Assoc J 1970;102(12):1286-7
21. Jarventausta K, Leinonen E. Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. Acta Psychiatr Scand 2000;102(3):231-3
22. Eberlein-Konig B, Bindl A, Przybilla B. Phototoxic properties of neuroleptic drugs. Dermatology 1997;194(2):131-5
23. Schreinzer D, Frey R, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S. Different fatal toxicity of neuroleptics identified by autopsy. Eur Neuropsychopharmacol 2001;11(2):117-24
24. Koski, A, Ojanpera I, Vuori E. Interaction of alcohol and drugs in fatal poisonings. Hum Experimental Toxicol 2003;22(5):281-7
25. Daniel WA, Syrek M, Rylko Z, Kot M. Effects of phenothiazine neuroleptics on the rate of caffeine demethylation and hydroxylation in the rat liver. Pol J Pharmacol 2001;53(6):615-21
26. Gram LF, Hansen MG, Sindrup SH, et al. Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 1993;15(1):18-24